Abstract: The invention provides compositions and methods for engineering E. coli or other host production bacterial strains to produce fucosylated oligosaccharides, and the use thereof in the prevention or treatment of infection.
Type:
Grant
Filed:
July 25, 2012
Date of Patent:
May 12, 2015
Assignee:
Glycosyn LLC
Inventors:
Matthew Ian Heidtman, Massimo Merighi, John M. McCoy
Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
Type:
Application
Filed:
November 6, 2014
Publication date:
May 7, 2015
Inventors:
Ken Boakye, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
Abstract: A recombinant microorganism having increased iron-regulated ABC transporter activity and increased hydroxycarboxylic acid production, as well as a method of producing a hydroxycarboxylic acid using the recombinant microorganism, and a method of producing the recombinant microorganism.
Type:
Application
Filed:
November 5, 2014
Publication date:
May 7, 2015
Inventors:
Hwayoung Cho, Jinhwan Park, Hongsoon Rhee, Kwangmyung Cho
Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
Type:
Application
Filed:
July 2, 2014
Publication date:
May 7, 2015
Inventors:
Oliver HILL, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
Abstract: The present invention provides herein a polynucleotide sequence encoding the tubby-like protein, CaTLP1, from chickpea (Cicer arientium L.) that is responsive to abiotic stress and is involved in plant growth and development. Further, the recombinant DNA construct and recombinant vector comprising the polynucleotide sequence encoding CaTLP1, host cell comprising the recombinant vector and a process for producing a transgenic plant that expresses the CaTLP1 protein are also provided herein.
Abstract: The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided.
Abstract: Provided is a pharmaceutical composition for the treatment and/or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.
Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.
Type:
Application
Filed:
June 6, 2013
Publication date:
May 7, 2015
Inventors:
Santos Susin, Pierre Launay, Philippe Karoyan, Helene Merle-Beral
Abstract: [Problem] An object of the present invention is to provide an anti-human IL-23R antibody having excellent activity and/or cross-reactivity compared to conventional IL-23R antibodies, and means for using the antibody to prevent or treat various diseases such as ophthalmic disease, inflammatory bowel disease, or psoriasis in which human IL-23R is involved in pathogenesis. [Means for Solution] An anti-human IL-23R antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:10 or 14 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:6 or 18.
Abstract: Engineered multivalent and multispecific binding proteins that bind immune cell receptors and/or autoantigens are provided, along with methods of making and uses in the prevention, diagnosis, prognosis and/or treatment of disease.
Type:
Application
Filed:
October 6, 2014
Publication date:
May 7, 2015
Inventors:
Chee-Ho Choi, Tariq Ghayur, Ann Marshak-Rothstein, Krishna Moody
Abstract: The invention relates to variants of an antibody or antigen-binding fragment that binds specifically to an endosialin tumor endothelial marker 1 (TEM1), and prophylactic, diagnostic, and therapeutic methods using the same.
Abstract: Provided are isolated polypeptides having glucoamylase activity, catalytic domains, and polynucleotides encoding the polypeptides, catalytic domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains.
Abstract: The invention relates to compositions, including polynucleotide sequences, amino acid sequences, recombinant microorganisms, and recombinant microorganism cultures that produce compositions of fatty acids and derivatives having target aliphatic chain lengths and/or preferred percent saturation. Further, the invention relates to methods of making and using the compositions. The compositions and methods provide for high titers, high yields, and high productivities of fatty acids and derivatives thereof.
Type:
Application
Filed:
August 17, 2012
Publication date:
May 7, 2015
Applicant:
LS9, INC.
Inventors:
Eli S. Groban, Vikranth Arlagadda, Scott A. Frykman, Derek L. Greenfield, Zhihao Hu
Abstract: Nucleic acid molecules from cannabis has been isolated and characterized and encode polypeptides having aromatic prenyltransferase activity. Expression or over-expression of the nucleic acids alters levels of cannabinoid compounds. The polypeptides may be used in vivo or in vitro to produce cannabinoid compounds.
Abstract: The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one transporter protein that changes three-dimensional conformation upon specifically transporting its substrate. The transporter protein may be a nitrate transporter, a peptide transporter, or a hormone transporter. The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one mechanosensitive ion channel protein. The invention also provides for methods of using the fusion proteins of the present invention and nucleic acids encoding the fusion proteins.
Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
Abstract: A simple and inexpensive method for selectively culturing a microorganism which method makes it possible to selectively culture a microorganism of interest even without using a sterilization operation or an antibiotic substance is provided. The method according to the present invention selectively culturing a microorganism includes the step of culturing, in a culture medium containing phosphorous acid as a sole phosphorous source, a recombinant microorganism into which a phosphite dehydrogenase gene has been introduced.
Abstract: The present invention relates to glucose dehydrogenase [NAD(P)+GDH] using nicotinamide adenine dinucleotide or nicotinamide adenine dinucleotide phosphate as a coenzyme, in which the thermal stability and/or the resistance to an organic solvent in the absence of sodium chloride are improved.
Abstract: Systems, compounds and methods for the conversion of C1 carbon compounds to higher carbon compounds useful for the generation of commodity compounds.
Type:
Grant
Filed:
September 15, 2011
Date of Patent:
May 5, 2015
Assignee:
University of Washington through its Center for Commercialization
Inventors:
Justin Siegel, David Baker, Amanda Lee Smith, Mary E. Lidstrom, Catherine Louw
Abstract: The present invention relates to ?-amylase variants that are stabilized to dimerization and/or multimerization, in particular at elevated temperatures or high pH, by point mutagenesis of positively polarized or charged or neutral surface amino acids to give more negatively polarized or charged amino acids. The invention further relates to methods of increasing the stability of an ?-amylase to dimerization and/or multimerization brought about by electrostatic interactions whereby at least one amino acid residue on the surface of the starting molecule, which makes a neutral or positively polar or charged contribution to the electrostatic potential of said molecule, is replaced with a more negatively polar or negatively charged amino acid residue. The ?-amylase variants obtained thereby exhibit better stability to influences of the solvent, increased processivity, and are suited for numerous industrial areas of use, in particular as active ingredients in detergents and cleansers.
Type:
Application
Filed:
June 10, 2014
Publication date:
April 30, 2015
Inventors:
Cornelius BESSLER, Susanne WIELAND, Karl-Heinz MAURER
Abstract: The present invention relates to the development of new derivatives of a bacterial plasminogen activator, Staphylokinase (SAK), having one or more amino acid residues with single or multiple cysteines at the amino and/or carboxy terminal ends and their conjugation with PEG (Polyethylene Glycol), resulting in new Staphylokinase derivatives that display altered oligomeric states, enhanced thermal and protease stability and extended plasma half-life. Also included is the cloning and expression in a suitable bacterial host; purification of Staphylokinase derivatives to homogeneity and their chemical modification by integrating a PEG molecule to create new biologically active Staphylokinases having higher protein stability and improved in vivo plasma half life, that may enhance the clinical potential of Staphylokinase in thrombolytic therapy for the treatment of cardiovascular diseases.
Abstract: The present application relates to glycoengineered outer membrane vesicles obtained from recombinant, gram-negaetive bacteria comprising hetereologous DNA encoding an enzyme or enzymes that produce a heterologous glycan that replaces all or a portion of the naturally-occurring O antigen in the lipopolysaccharides of the bacteria. Also provided by the present application are immunogenic compositions and vaccines prepared from the glycoengineered outer membrane vesicles expressing the heterologous glycans at their surface.
Type:
Application
Filed:
April 26, 2013
Publication date:
April 30, 2015
Applicant:
The Governors of the University of Alberta
Inventors:
Mario Feldman, Nancy Price, Fatima Garcia-Quintanilla, Maria Veronica Ielmini
Abstract: A monoclonal antibody recognizing the extracellular region of LAMP5 was produced. The produced antibody demonstrated antibody-dependent cell-mediated cytotoxic activity, and/or cell growth inhibitory activity in the presence of a toxin-labeled secondary antibody, against a multiple myeloma cell line.
Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.
Abstract: The present disclosure provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents. The present disclosure provides engineered proline hydroxylase biocatalysts, polynucleotides encoding the biocatalysts. methods of their preparation, and processes for preparing hydroxylated compounds using these engineered biocatalysts.
Type:
Application
Filed:
May 7, 2013
Publication date:
April 30, 2015
Inventors:
Haibin Chen, Yong Koy Bong, Fabien L. Cabirol, Anupam Gohel Prafulchandra, Tao Li, Jeffrey C. Moore, Martina Quintanar-Audelo, Yang Hong, Steven J. Collier, Derek Smith
Abstract: The present invention provides various combinations of genetic modifications to a transformed host cell that provide increase conversion of carbon to a chemical product. The present invention also provides methods of fermentation and methods of making various chemical products.
Type:
Application
Filed:
March 17, 2014
Publication date:
April 30, 2015
Applicant:
OPX Biotechnologies, Inc.
Inventors:
Hans LIAO, Christopher Patrick MERCOGLIANO, Travis Robert WOLTER, Michael Tai Man LOUIE, Wendy Kathleen RIBBLE, Tanya LIPSCOMB, Eileen Colie SPINDLER, Michael D LYNCH
Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
Type:
Application
Filed:
May 13, 2013
Publication date:
April 30, 2015
Inventors:
Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
Abstract: Eukaryotic protein-coding messenger RNAs and non-coding microRNAs are naturally transcribed by type II RNA polymerases (pol-2) but not prokaryotic RNA polymerases. As a result, current eukaryotic RNA and protein production is performed either using eukaryotic pol-2 promoters in hybridomas or mammalian cells or using prokaryotic promoters in bacterial cells. However, because prokaryotic RNA transcription tends to be error-prone, frequent mutation is a big problem. Also, growing hybridomas or mammalian cells is relatively laborious and costly. To overcome these problems, the present invention provides a novel inducible composition and method for producing eukaryotic RNAs and/or their related peptides/proteins directly using eukaryotic pol-2 promoter-driven gene expression in fast growing bacteria, without the need of changing to prokaryotic promoters or growing hybridomas/mammalian cells.
Abstract: Described is a method for generating isoprenol through a biological process. More specifically, described is a method for producing isoprenol from mevalonate.
Type:
Application
Filed:
April 4, 2013
Publication date:
April 30, 2015
Inventors:
Marc Delcourt, Maria Anissimova, Philippe Marliere
Abstract: Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.
Abstract: The present invention relates to isolated polypeptides having alpha-glucuronidase activity, catalytic domains and polynucleotides encoding the polypeptides, catalytic domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides or catalytic domains.
Type:
Application
Filed:
April 22, 2013
Publication date:
April 23, 2015
Inventors:
Johan Börjesson, Anders Vikø-Nielsen, Nikolaj Spodsberg, Kristian Krogh
Abstract: Recombinant butyraldehyde dehydrogenases (Blds) with improved production of 1,4-BDO, as well as recombinant microorganisms comprising polynucleotides encoding the recombinant Blds, and methods of producing 1,4-BDO by using the recombinant microorganisms.
Type:
Application
Filed:
October 1, 2014
Publication date:
April 23, 2015
Inventors:
Jinhwan Park, Pyungcheon Lee, Jaechan Park, Youngmin Lee, Wooyong Lee, Jinwoo Park, Kwangmyung Cho, Heejin Hwang
Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.
Abstract: The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
Abstract: The present invention relates to use of Caminibacter carbonic anhydrase in CO2 extraction, e.g., from flue gas, natural gas, biogas or ambient air. The Caminibacter carbonic anhydrases are especially well suited for these purpose due to their extreme thermostability.
Abstract: An L-threonine-producing Escherichia coli including a pathway selected from the group consisting of a pathway that produces acetaldehyde from acetyl-CoA with acetaldehyde dehydrogenase, and a pathway that produces L-threonine from acetaldehyde and glycine with threonine aldolase, and a pathway that produces 2-amino-3-oxobutyrate from glycine and acetyl-CoA with glycine C-acetyltransferase, and a pathway that produces L-threonine from 2-amino-3-oxobutyrate with threonine dehydrogenase.
Abstract: This document describes biochemical pathways for producing glutaric acid, 5-aminopentanoic acid, 5-hydroxypentanoic acid, cadaverine or 1,5-pentanediol by forming one or two terminal functional groups, comprised of carboxyl, amine or hydroxyl group, in a C5 backbone substrate such as D-proline.
Type:
Application
Filed:
August 27, 2014
Publication date:
April 23, 2015
Inventors:
Adriana Leonora Botes, Alex Van Eck Conradie
Abstract: The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Type:
Application
Filed:
October 16, 2014
Publication date:
April 23, 2015
Inventors:
Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT
Abstract: The present invention provides nanoparticles and compositions of various constructs that combine meta-stable viral proteins (e.g., RSV F protein) and self-assembling molecules (e.g., ferritin, HSPs) such that the pre-fusion conformational state of these key viral proteins is preserved (and locked) along with the protein self-assembling into a polyhedral shape, thereby creating nanoparticles that are effective vaccine agents. The invention also provides nanoparticles comprising a viral fusion protein, or fragment or variant thereof, and a self-assembling molecule, and immunogenic and vaccine compositions including the same.
Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.
Type:
Application
Filed:
October 27, 2014
Publication date:
April 23, 2015
Inventors:
Laura SERINO, Maria Rita FONTANA, Danilo GOMES MORIEL
Abstract: The present invention concerns wild-strains of Chikungunya virus isolated from patients exhibiting severe forms of infection and stemming from a human arbovirosis epidemy. The present invention also concerns polypeptide sequences and fragment thereof derived from their genome, the polynucleotide encoding same and their use as diagnostic products, as vaccine and/or as immunogenic compositions.
Type:
Application
Filed:
July 18, 2014
Publication date:
April 23, 2015
Applicant:
INSTITUT PASTEUR
Inventors:
PHILIPPE DESPRES, ANNE-CLAIRE BREHIN, VALERIE MARECHAL, PIERRE CHARNEAU, PHILIPPE SOUQUE
Abstract: The present invention relates to nucleic acids encoding peptides capable of binding to actin. The nucleic acids encoding the peptides are useful in methods for detecting actin in vitro or in living cells.
Type:
Application
Filed:
January 9, 2015
Publication date:
April 23, 2015
Inventors:
Roland Wedlich-Soldner, Michael Sixt, Julia Riedl, Alvaro Crevenna
Abstract: Antibodies and antibody fragments that bind to human TIM-1 on the BED face of the protein are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit or reduce TIM-1 binding to phosphatidylserine, inhibit or reduce TIM-1 binding to dendritic cells, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.
Type:
Application
Filed:
November 16, 2012
Publication date:
April 23, 2015
Inventors:
Veronique Bailly, Ellen Garber, Paul D. Rennert, Nicholas Joseph Lennemann, Wendy Jean Maury, Sven Henrik Moller-Tank
Abstract: The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.
Abstract: This disclosure provides anti-human cytomegalovirus antibodies and methods of treatment, prophylaxis, detection, and diagnosis using the same. In another aspect, the disclosure features therapeutic, prophylactic, and/or diagnostic compositions for human cytomegalovirus infection or for a human cytomegalovirus-related disease that include a binding agent (e.g., antibody) or polynucleotide disclosed herein. In some embodiments, the composition is formulated for ocular or topical administration. The compositions can further include one or more human cytomegalovirus-neutralizing antibodies, an intravenous immunoglobulin preparation, and/or one or more antiviral compounds (e.g., ganciclovir, foscamet, cidofovir, or valganciclovir).
Type:
Application
Filed:
April 30, 2013
Publication date:
April 23, 2015
Inventors:
Shuji Sato, Sean Andre Beausoleil, Wan Cheung Cheung, Roberto D. Polakiewicz